ASSEMBLY BIOSCIENCES, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Assembly Biosciences completed a $115 million gross financing and expanded ABI-6250 clinical development into cholestatic liver diseases (PBC/PSC), with Phase 2 anticipated Q1 2027. Cash position reached $320.4M (June 30, 2026 vs. $226.6M March 31, 2026), projected to fund operations into 2029, including a $75M Gilead collaboration extension payment due Q4 2026. GS-1179 (HSV program, exclusively licensed to Gilead) advanced to Phase 2 by year-end 2026; Assembly retains option for 40% U.S. cost-profit share.
Why this rating
Financing ($115M) is 118% of market cap—dramatically extends runway and de-risks near-term survival. Pipeline expansion (ABI-6250) into new indications plus Gilead collaboration optionality are material strategic advances for ~$98M company.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.